Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.51 USD | -2.33% | -7.38% | -64.85% |
Summary
- On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
Strengths
- For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.
Weaknesses
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- Low profitability weakens the company.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
- For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
Ratings chart - Surperformance
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-64.85% | 2.89M | - | ||
+40.80% | 53.67B | B- | ||
+35.79% | 38.86B | A | ||
-8.05% | 38.76B | B | ||
-8.98% | 27.27B | C | ||
+10.69% | 25.91B | B- | ||
-16.21% | 20.29B | B | ||
+31.00% | 12.78B | B+ | ||
+28.51% | 12.18B | C+ | ||
-1.67% | 11.96B | B+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- NBY Stock
- Ratings NovaBay Pharmaceuticals, Inc.